AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Jul 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-07-12

Reporting Person: Campbell Bradley L (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-12	Common Stock	S	1500	$12.5057	Disposed	813654	Direct
2023-07-13	Common Stock	S	6800	$12.5134	Disposed	806854	Direct

Footnotes

F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.51. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.54 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.